Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease
Liver International · 2026-06 · 46 (6)
DOI: 10.1111/liv.70679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 08.05.2026. Verfasst von Gang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Group VI Phospholipases A2, Hepatocytes, Myeloid Cells, Fatty Liver. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background and Aims Polymorphisms of group VIA calcium‐independent phospholipase A2 (iPLA2β or PLA2G6) are associated with Type‐2 diabetes, blood lipids and inflammation. Global deficiency in iPLA2β‐null mice elicited protection against hepatic steatosis but not hepatic inflammation after high‐fat diet (HFD) feeding. We aimed to determine whether HFD‐induced phenotypes could be affected by PLA2G6 deficiency specifically in myeloid cells and hepatocytes.
Methods
Male control Pla2g6 flox/flox , myeloid‐(Pla2g6 M−/− ) and hepatocyte‐(Pla2g6 Hep−/− ) specific Pla2g6‐deficient mice were subjected to chow or HFD feeding for 6 months. The contents of phospholipids, white blood cell counts, plasma cytokines and metabolic parameters were quantified. Hepatic inflammation, lymphopoiesis and fibrosis were evaluated by histology, immunohistochemistry, Western blot and qRT‐PCR.
Results
Increased levels of phospholipids were observed in bone marrow‐derived macrophages and livers from chow‐fed Pla2g6 M−/− and Pla2g6 Hep−/− mice, respectively. After HFD feeding, Pla2g6 M−/− mice displayed a further increase in hepatic recruitment of granulocytes and lymphocytes, plasma cytokines/lipids, liver inflammation/fibrosis as well as metabolic parameters including plasma lipoproteins, plasma/liver lipopolysaccharides, liver triglycerides/non‐esterified free fatty acids, plasma insulin/leptin and HOMA‐IR. These metabolic parameters were further increased in HFD‐fed Pla2g6 Hep−/− mice; however, they were protected from hepatic programmed cell death and inflammatory fibrosis with attenuation of plasma lipids and cytokines. Remarkably, these metabolic parameters were also increased in both mutants under chow.
Conclusion
Myeloid‐ and hepatocyte‐PLA2G6 deficiency elicited aggravation and protection against HFD‐induced hepatic inflammation, respectively. However, PLA2G6 deficiency in both cell types exacerbated insulin resistance. PLA2G6 inactivation specifically in hepatocytes may provide a potential therapy option to alleviate diet‐induced liver inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Gang Li, Uta Merle, Walee Chamulitrat
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Li, G., Staffer, S., Tuma-Kellner, S., Merle, U., & Chamulitrat, W. (2026). Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International, 46(6). https://doi.org/10.1111/liv.70679
Vancouver
Li G, Staffer S, Tuma-Kellner S, Merle U, Chamulitrat W. Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2026;46(6). doi:10.1111/liv.70679
BibTeX
@article{Li2026,
author = {Li, Gang and Staffer, Simone and Tuma-Kellner, Sabine and Merle, Uta and Chamulitrat, Walee},
title = {Distinct Roles of Myeloid‐ and Hepatocyte‐PLA2G6 Deletion in Mice With Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Liver International},
year = {2026},
volume = {46},
number = {6},
doi = {10.1111/liv.70679}
}
EUVIMED